Advanced Search
REVIEW ARTICLE
Korean J Pediatr 2011 March;54(3) :95-105.
doi:https://doi.org/10.3345/kjp.2011.54.3.95
Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia
Eun Sun Yoo (Yoo ES)
Division of Pediatric Hematology-Oncology, Department Pediatrics, Ewha Womans University, School of Medicine, Seoul, Korea
Corresponding Author: Eun Sun Yoo ,Tel: +82.2-2650-5586, Fax: +82.2-2653-3718, Email: eunsyoo@ewha.ac.kr
Copyright © 2011 by The Korean Pediatric Society
ABSTRACT
Since the successful introduction of all-trans-retinoic acid (ATRA) and its combination with anthracycline-containing chemotherapy, the prognosis for acute promyelocytic leukemia (APL) has markedly improved. With ATRA and anthracycline-based-chemotherapy, the complete remission rate is greater than 90%, and the long-term survival rate is 70‒89%. Moreover, arsenic trioxide (ATO), which was introduced for APL treatment in 1994, resulted in excellent remission rates in relapsed patients with APL, and more recently, several clinical studies have been designed to explore its role in initial therapy either alone or in combination with ATRA. APL is a rare disease in children and is frequently associated with hyperleukocytosis, which is a marker for higher risk of relapse and an increased incidence of microgranular morphology. The frequency of occurrence of the promyelocytic leukemia/ retinoic acid receptor-alpha (PML/RAR) isoforms bcr 2 and bcr 3 is higher in children than in adults. Although recent clinical studies have reported comparable long-term survival rates in patients with APL, therapy for APL in children is challenging because of the risk of early death and the potential long-term cardiac toxicity resulting from the need to use high doses of anthracyclines. Additional prospective, randomized, large clinical trials are needed to address several issues in pediatric APL and to possibly minimize or eliminate the need for chemotherapy by combining ATRA and ATO. In this review article, we discuss the molecular pathogenesis, diagnostic progress, and most recent therapeutic advances in the treatment of children with APL.
Keywords: Acute promyelocytic leukemia | Child | PML-RARA | Tretinoin | Arsenic trioxide | Anthracycline
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
  via Pubmed
Full text via PMC  Full text via PMC
via Pubreader  via PubReader
Download Citation  Download Citation
Supplementary Material  Supplementary Material
  E-Mail
Share:      
METRICS
1,451
View
6
Download
Approaches to the diagnosis and management of chronic urticaria in children  2015 May;58(5)
Role of colonoscopy in the diagnosis and treatment of pediatric lower gastrointestinal disorders  2010 September;53(9)
Recent Advances in the Treatment of Childhood Leukmia  2003 January;46(1)
Anticancer Effect of Arsenic Trioxide in Acute Promyelocytic Leukemia  2000 March;43(3)
Recent Advances in Treatment of Childhood Cancers  1999 July;42(7)
Register for e-submission
Register here to access the e-submission system of Korean J Pediatr for authors and reviewers.
Manuscript Submission
To submit a manuscript, please visit the Korean J Pediatr e-submission management system at http://submit.kjp.or.kr, read the Instructions for Authors, and log into the Korean J Pediatr e-submission system. For assistance with manuscript submission, please contact: kjpped@gmail.com.
Free archive
Anyone may access any past or current articles without logging in.
Korean Pediatric Society Office
#1606, Seocho World Officetel, 19 Seoun-ro, Seocho-gu, Seoul 137-070, Korea
TEL : +82-2-3473-7305    FAX : +82-2-3473-7307   E-mail: kjpped@gmail.com
BrowseCurrent IssueFor Authors and ReviewersAbout
Copyright© The Korean Pediatric Society. All right reserved.